ES2915901T3 - Compuestos tetracíclicos condensados, composiciones y usos de los mismos - Google Patents

Compuestos tetracíclicos condensados, composiciones y usos de los mismos Download PDF

Info

Publication number
ES2915901T3
ES2915901T3 ES17736213T ES17736213T ES2915901T3 ES 2915901 T3 ES2915901 T3 ES 2915901T3 ES 17736213 T ES17736213 T ES 17736213T ES 17736213 T ES17736213 T ES 17736213T ES 2915901 T3 ES2915901 T3 ES 2915901T3
Authority
ES
Spain
Prior art keywords
pyrrolo
mmol
diazepin
bromo
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17736213T
Other languages
English (en)
Spanish (es)
Inventor
Casey Mccomas
Michael Serrano-Wu
Joseph VACCA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tabomedex Biosciences Inc
Original Assignee
Tabomedex Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tabomedex Biosciences Inc filed Critical Tabomedex Biosciences Inc
Application granted granted Critical
Publication of ES2915901T3 publication Critical patent/ES2915901T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES17736213T 2016-01-04 2017-01-04 Compuestos tetracíclicos condensados, composiciones y usos de los mismos Active ES2915901T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662274640P 2016-01-04 2016-01-04
PCT/US2017/012092 WO2017120164A1 (en) 2016-01-04 2017-01-04 Fused quadracyclic compounds, compositions and uses thereof

Publications (1)

Publication Number Publication Date
ES2915901T3 true ES2915901T3 (es) 2022-06-27

Family

ID=59226993

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17736213T Active ES2915901T3 (es) 2016-01-04 2017-01-04 Compuestos tetracíclicos condensados, composiciones y usos de los mismos

Country Status (8)

Country Link
US (2) US10059718B2 (cg-RX-API-DMAC7.html)
EP (1) EP3400228B1 (cg-RX-API-DMAC7.html)
JP (1) JP7068185B2 (cg-RX-API-DMAC7.html)
CN (1) CN108779123B (cg-RX-API-DMAC7.html)
AU (1) AU2017205320B2 (cg-RX-API-DMAC7.html)
ES (1) ES2915901T3 (cg-RX-API-DMAC7.html)
TW (1) TWI730027B (cg-RX-API-DMAC7.html)
WO (1) WO2017120164A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof
CN107879989B (zh) * 2017-11-29 2020-01-03 重庆市中药研究院 具有生物活性的3,4,5-取代苯并二氮卓2-酮类药物分子及其制备方法
WO2022150707A1 (en) * 2021-01-11 2022-07-14 Tabomedex Biosciences, Inc. Fused quadracyclic compounds, compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521534A (en) 1983-12-19 1985-06-04 Ayerst, Mckenna & Harrison, Ltd. Imidazo[2,1-a]pyrrolo[2,1-c][1,4]benzodiazepine derivatives, methods of preparation and use
US4596799A (en) 1985-01-29 1986-06-24 Ciba-Geigy Corporation 9H-pyrrolo[2,1-c]-1,2,4-triazolo[4,3-a][1,4]benzodiazepines
TWI239333B (en) * 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
MXPA05006568A (es) 2002-12-20 2005-09-22 Pharmacia Corp Compuestos de pirazol aciclico para la inhibicion de proteina cinasa-2 activada por proteina cinasa activada por mitogenos.
KR20150133172A (ko) 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
WO2014146164A1 (en) * 2013-03-22 2014-09-25 Lifi Labs Inc Color selection
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof

Also Published As

Publication number Publication date
US10562909B2 (en) 2020-02-18
CA3010213A1 (en) 2017-07-13
TW201726681A (zh) 2017-08-01
WO2017120164A1 (en) 2017-07-13
CN108779123A (zh) 2018-11-09
JP7068185B2 (ja) 2022-05-16
EP3400228A4 (en) 2019-08-14
US20180319809A1 (en) 2018-11-08
AU2017205320A1 (en) 2018-07-05
TWI730027B (zh) 2021-06-11
US20170190713A1 (en) 2017-07-06
CN108779123B (zh) 2025-08-19
JP2019501971A (ja) 2019-01-24
EP3400228B1 (en) 2022-04-13
AU2017205320B2 (en) 2021-06-24
EP3400228A1 (en) 2018-11-14
US10059718B2 (en) 2018-08-28

Similar Documents

Publication Publication Date Title
US9603854B2 (en) Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
CN107949559B (zh) 作为irak4调节剂的双环稠合杂芳基或芳基化合物
AU2010275196B2 (en) Fused aminodihydropyrimidone derivatives
US20240025907A1 (en) QUINAZOLINE PAN-KRas INHIBITORS
TWI794232B (zh) 激酶抑制劑及其用途
US20230072276A1 (en) Azaquinazoline pan-KRas inhibitors
JP2024513881A (ja) オキサゼピン化合物及びがんの治療におけるその使用
HUE028723T2 (en) Piperidin-4-yl azetidine derivatives as JAK-1 inhibitors
KR20250117446A (ko) 피리미딘 함유 다중 융합 고리계 유도체 억제제, 이의 제조 방법과 응용
CN102458116A (zh) Iap抑制剂
CN112584898A (zh) P2x3受体拮抗剂
ES2915901T3 (es) Compuestos tetracíclicos condensados, composiciones y usos de los mismos
TW202417458A (zh) 調節her2的化合物及方法
KR20230157467A (ko) 모세혈관 확장성 운동실조증 돌연변이(atm) 키나아제의 선택적 조절제 및 이의 용도
HK40006173A (en) Fused quadracyclic compounds, compositions and uses thereof
HK40006173B (zh) 稠合四环化合物、其组合物和用途
WO2025153712A1 (en) Tricyclic compounds, preparation thereof and therapeutic uses as erk5 inhibitors
CN120574242A (zh) 含嘧啶多元并环类衍生物抑制剂、其制备方法和应用